Dr. Jona Ashok Hattangadi-Gluth, MD

Dr. Hattangadi-Gluth practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Hattangadi-Gluth's NPI, 1467625491, was assigned on April 10, 2008. Dr. Hattangadi-Gluth graduated from Harvard Medical School in 2007. Dr. Hattangadi-Gluth holds California license A122308.

Dr. Hattangadi-Gluth's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Hattangadi-Gluth's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Hattangadi-Gluth is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Hattangadi-Gluth to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hattangadi-Gluth practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hattangadi-Gluth's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Hattangadi-Gluth is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Hattangadi-Gluth's licenses on file in 3 states: California, Massachusetts and Virginia.

Dmand AI lists brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, head & neck cancer radiation, lung cancer radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Hattangadi-Gluth treats.

CMS data shows 1,093 Medicare services from Dr. Hattangadi-Gluth across 13 procedure codes in 2024, for 186 Medicare patients. Medicare paid $105,486 for them.

CMS counts 186 Medicare patients who saw Dr. Hattangadi-Gluth in 2024. The largest group is 65 to 74, with 80 patients. 68% of them have high blood pressure, and 67% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hattangadi-Gluth's median patient age at 63, with 54% women.

In 2024, Dr. Hattangadi-Gluth wrote 19 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $189 in total drug cost. In 2020, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Hattangadi-Gluth for performance year 2024, reported as part of a group. Dr. Hattangadi-Gluth accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hattangadi-Gluth as offering telehealth.

Dmand AI links 91 papers to Dr. Hattangadi-Gluth, published from 2011 to 2025. 2017 was the busiest year, with 11. The most frequent topics are Brain Neoplasms, Magnetic Resonance Imaging and Glioma. Dr. Hattangadi-Gluth has published most often in Int J Radiat Oncol Biol Phys. Dr. Hattangadi-Gluth's most frequent co-authors are Nikdokht Farid, MD, Tyler Michael Seibert, MD, PhD and Minh-Phuong Huynh-Le, MD.

Dmand AI links Dr. Hattangadi-Gluth to 2 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Brain Neoplasms, Cognitive Dysfunction and Central Nervous System Neoplasms.

CMS Open Payments shows 13 general payments to Dr. Hattangadi-Gluth from 2 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 42% of the total. Varian Medical Systems, Inc. paid the most, $4,657.

Dr. Hattangadi-Gluth graduated from Harvard Medical School in 2007.

Dr. Hattangadi-Gluth is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.